Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

View the 50 largest pharmaceutical companies in the world listings here

Astellas Pharma in the Drug Discovery & Development Pharma 50

Astellas Pharma

Rank: 27

2021 Rank: 23

Tokyo, Japan
www.astellas.com

2021 Revenues ($USD) : $11,375,892,207
2021 Revenues (foreign currencies) : JP¥1,249,528,000,000
2021 R&D spend : $2,043,781,865
2021 Number of Employees : 15,455
Fiscal Year End : 3/31/2021
Leader : CEO Kenji Yasukawa

Tokyo-based Astellas Pharma had continued success with its Xtandi (enzalutamide) prostate-cancer-treating drug. Other bestsellers include Xospata (gilteritinib) and Padcev (enfortumab vedotin). In addition, Prograf (tacrolimus) also remains a core product in its portfolio. —BB

Astellas Northbrook

[Astellas Northbrook Campus. Image courtesy of the Teska Associates architectural firm that designed the campus.]

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE